argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 44.00B +38.2% |
| Revenue (ttm) | 3.61B +88.4% |
| Net Income | 1.10B +55.1% |
| EPS | 16.67 +53.1% |
| Shares Out | 62.19M |
| PE Ratio | 42.45 |
| Forward PE | 29.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,963 |
| Average Volume | 102,943 |
| Open | 705.00 |
| Previous Close | 707.60 |
| Day's Range | 702.00 - 708.20 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.09 |
| RSI | 66.16 |
| Earnings Date | May 7, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, O...
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the...
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of pat...
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthen...
Argenx Touts Positive Phase 3 Eye Disease Study Results
Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx Highlights 2026 Strategic Priorities
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
argenx Announces Leadership Transition Marking Next Evolution of Growth
Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with mode...
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday.
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any b...
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results sho...
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART's sustained...
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a s...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
argenx to Present at Upcoming Investor Conferences
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...